ER
Therapeutic Areas
Acadia Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NUPLAZID® (pimavanserin) | Parkinson's Disease Psychosis (PDP) | Approved/Commercial |
| DAYBUE® (trofinetide) | Rett Syndrome | Approved/Commercial |
| Pimavanserin | Alzheimer's Disease Psychosis (ADP) | Phase 3 |
| ACP-101 (intranasal carbetocin) | Prader-Willi Syndrome | Phase 2/3 |
| ACP-204 | Undisclosed CNS indication | Phase 1 |
Leadership Team at Acadia Pharmaceuticals
JM
Jonathan M. Poole
Board of Directors
SD
Steve Davis
President and Chief Executive Officer
MS
Mark Schneyer
Chief Financial Officer
DS
Dr. Sarfaraz Niazi
Chief Scientific Officer
DJ
Dr. Jeffrey D. Wiesen
Chief Medical Officer
BT
Brendan Teehan
Chief Legal Officer and Corporate Secretary
KG
Kristina G. Copp
Chief Accounting Officer
AD
Austin D. Kim
Executive Vice President, General Counsel